Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear hormone receptor that plays a key role in the differentiation of adipocytes. Activation of this receptor in liposarcomas and breast and colon cancer cells also induces cell growth inhibition and differentiation. In the present study, we show that PPARγ is expressed in human prostate adenocarcinomas and cell lines derived from these tumors. Activation of this receptor with specific ligands exerts an inhibitory effect on the growth of prostate cancer cell lines. Further, we show that prostate cancer and cell lines do not have intragenic mutations in the PPARγ gene, although 40% of the informative tumors have hemizygous deletions of this gene. Based on our preclinical data, we conducted a phase II clinical study in patients with advanced prostate cancer using troglitazone, a PPARγ ligand used for the treatment of type 2 diabetes. Forty-one men with histologically confirmed prostate cancer and no symptomatic metastatic disease were treated orally with troglitazone. An unexpectedly high incidence of prolonged stabilization of prostate-specific antigen was seen in patients treated with troglitazone. In addition, one patient had a dramatic decrease in serum prostate-specific antigen to nearly undetectable levels. These data suggest that PPARγ may serve as a biological modifier in human prostate cancer and its therapeutic potential in this disease should be further investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PCR protocols — A guide to methods and applications
(1990) · Trends in Genetics · doi:10.1016/0168-9525(90)90186-a · Cited by 11,781
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
Self-citationLandis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.8 · Cited by 3,068
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Self-citationmPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Self-citationKliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730
Self-citationDifferentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)
Warrell, R. P., Frankel, S. R., Miller, W. H., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105163242002 · Cited by 1,251
Cited by
PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth
Rosen, E. D., & Spiegelman, B. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100034200 · Cited by 1,175
Self-citationInternational Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,000
Self-citationDietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms
Larsson, S. C., Kumlin, M., Ingelman-Sundberg, M., & Wolk, A. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.6.935 · Cited by 950
Obesity and cancer: the role of dysfunctional adipose tissue
van Kruijsdijk, R. C. M., van der Wall, E., & Visseren, F. L. J. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0372 · Cited by 715
The Role of Adiponectin in Cancer: A Review of Current Evidence
Dalamaga, M., Diakopoulos, K. N., & Mantzoros, C. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1015 · Cited by 640
Cancer Chemoprevention by Carotenoids
Tanaka, T., Shnimizu, M., & Moriwaki, H. (2012) · Molecules · doi:10.3390/molecules17033202 · Cited by 589
Peroxisome-proliferator-activated receptors and cancers: complex stories
Michalik, L., Desvergne, B., & Wahli, W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1254 · Cited by 573
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3214 · Cited by 492
Pantuck, A. J., Leppert, J. T., Zomorodian, N., Aronson, W., Hong, J., Barnard, R. J., Seeram, N., Liker, H., Wang, H., Elashoff, R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2290 · Cited by 461
Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists
Grommes, C., Landreth, G. E., & Heneka, M. T. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01509-8 · Cited by 440
Krishnan, J., Suter, M., Windak, R., Krebs, T., Felley, A., Montessuit, C., Tokarska-Schlattner, M., Aasum, E., Bogdanova, A., Perriard, E., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.05.005 · Cited by 404
Vallée, A., & Lecarpentier, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00745 · Cited by 374
Patel, L., Pass, I., Coxon, P., Downes, C. P., Smith, S. A., & Macphee, C. H. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00225-1 · Cited by 365
15d-PGJ2: The anti-inflammatory prostaglandin?
Scher, J. U., & Pillinger, M. H. (2005) · Clinical Immunology · doi:10.1016/j.clim.2004.09.008 · Cited by 348
Inflammation and the development of pancreatic cancer
Farrow, B., & Evers, B. M. (2002) · Surgical Oncology · doi:10.1016/s0960-7404(02)00015-4 · Cited by 338
“Clinical studies have not been performed to evaluate the effects of TZDs in patients with pancreatic cancer, but in patients with prostate cancer troglitazone they produced a significant improvement in PSA levels [162].”
BackgroundE2Fs Regulate Adipocyte Differentiation
Fajas, L., Landsberg, R. L., Huss-Garcia, Y., Sardet, C., Lees, J. A., & Auwerx, J. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00190-9 · Cited by 321
Zhou, M., Chinnaiyan, A. M., Kleer, C. G., Lucas, P. C., & Rubin, M. A. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200207000-00012 · Cited by 297
Ameshima, S., Golpon, H., Cool, C. D., Chan, D., Vandivier, R. W., Gardai, S. J., Wick, M., Nemenoff, R. A., Geraci, M. W., & Voelkel, N. F. (2003) · Circulation Research · doi:10.1161/01.res.0000073585.50092.14 · Cited by 292
APC-dependent suppression of colon carcinogenesis by PPARγ
Girnun, G. D., Smith, W. M., Drori, S., Sarraf, P., Mueller, E., Eng, C., Nambiar, P., Rosenberg, D. W., Bronson, R. T., Edelmann, W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162480299 · Cited by 277
Self-citationAnti‐tumor mechanisms of valproate: A novel role for an old drug
Blaheta, R. A., & Cinatl, J. (2002) · Medicinal Research Reviews · doi:10.1002/med.10017 · Cited by 269
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
Knouff, C., & Auwerx, J. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0036 · Cited by 256
Burstein, H. J., Demetri, G. D., Mueller, E., Sarraf, P., Spiegelman, B. M., & Winer, E. P. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024038127156 · Cited by 228
“Thiazolidinediones have also been shown to alter in vitro growth patterns in models of colorectal cancer [9] and prostate cancer [10, 11].”
BackgroundSelf-citationTarget Genes of Peroxisome Proliferator-activated Receptor γ in Colorectal Cancer Cells
Gupta, R. A., Brockman, J. A., Sarraf, P., Willson, T. M., & DuBois, R. N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103779200 · Cited by 215
Self-citationInhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor.
Cheng, S., Brzostek, S., Lee, S. R., Hollenberg, A. N., & Balk, S. P. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.7.0870 · Cited by 121
Rosiglitazone and Risk of Cancer
Monami, M., Lamanna, C., Marchionni, N., & Mannucci, E. (2008) · Diabetes Care · doi:10.2337/dc07-2308 · Cited by 97
New factors in the regulation of adipose differentiation and metabolism
Holst, D., & Grimaldi, P. A. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200206000-00002 · Cited by 93
Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer
Fenner, M. H., & Elstner, E. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.557 · Cited by 88
Metadata
- Authors
- Mueller, E., Smith, M., Sarraf, P., Kroll, T., Aiyer, A., Kaufman, D. S., Oh, W., Demetri, G., Figg, W. D., Zhou, X.-P., Eng, C., Spiegelman, B. M., & Kantoff, P. W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-09-12
- Volume
- 97
- Issue
- 20
- Pages
- 10990-10995
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2003699768
- Cited by
- 426
- References
- 24
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.